methoxy-morpholinyl-doxorubicin has been researched along with Neutropenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, L; Bissett, D; Breda, M; Cassidy, J; Kaye, SB; Pacciarini, MA; Poggesi, I; Strolin-Benedetti, M; Vasey, PA; Wilson, P | 1 |
| Bakker, M; de Vries, EG; Domenigoni, L; Droz, JP; Groen, HJ; Hanauske, AR; Pacciarini, MA; Pianezzola, E; van Oosterom, AT; van Weissenbruch, F; Verweij, J | 1 |
2 trial(s) available for methoxy-morpholinyl-doxorubicin and Neutropenia
| Article | Year |
|---|---|
Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).
Topics: Adult; Aged; Doxorubicin; Female; Humans; Liver; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1995 |
Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Neutropenia; Thrombocytopenia; Treatment Outcome | 1998 |